First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early P arkinson’s disease ; expected to initiate in 2021 Prothena to earn a $60 million clinical milestone upon first patient dosed DUBLIN, Ireland , Oct.
DUBLIN, Ireland , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
DUBLIN, Ireland , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investor
First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor function and biomarkers, in patients with early Parkinson’s disease Significantly reduced decline
DUBLIN, Ireland , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that
DUBLIN, Ireland , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated
DUBLIN, Ireland , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline DUBLIN, Ireland , Aug.
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for
DUBLIN, Ireland , July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it
DUBLIN, Ireland , May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare
Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash and restricted cash position of $355.4 million provides funding to advance a broad pipeline DUBLIN, Ireland , May 06, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a
DUBLIN, Ireland , April 29, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020 , after the close of the
DUBLIN, Ireland , April 24, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020 . The meeting will convene as scheduled at The Merrion Hotel , Upper
DUBLIN, Ireland , April 22, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early
